Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06458712 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
A Phase 1 study of Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases), sponsored by Duke Street Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 13
- Study locations
NCT06458712 is a Phase 1 study of Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases) that is actively recruiting participants, run by Duke Street Bio. The registered enrollment target is 90 participants. The trial reports 13 study locations across 4 states.
The verdict
NCT06458712, a Phase 1 study of Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases), is actively recruiting participants, sponsored by Duke Street Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 13
- Study locations
Study Summary
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage inter-participant Dose Escalation Phase followed by a Dose Expansion Phase.
Conditions Studied
Interventions
- DRUG DSB2455
Study Locations (13)
Other
- Institut Bergonie - Bordeaux
- Institut Godinot - Reims
- Hospital Universitari Vall d'Hebron - Barcelona
- START Barcelona, CIOCC, Hospital Universitario Nou Delfos - Barcelona
- Hospital Universitario Reina Sofía - Córdoba
- Hospital 12 de Octubre - Madrid
- START Madrid-CIOCC, Hospital Universitario HM Sanchinarro - Madrid
- Hospital Universitario Virgen de la Victoria - Málaga
- Universitary Hospital Virgen del Rocio - Seville
- Instituto Valenciano de Oncologia - Valencia
Connecticut
- Yale Cancer Center - Yale New Haven Hospital - New Haven
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
La Rioja
- START La Rioja, Hospital Universitario San Pedro - Logroño
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06458712
The ClinicalTrials.gov registry entry for NCT06458712 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke Street Bio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases) appearing as the primary indexed condition, and to 1 intervention - of which DSB2455 is the first listed.
NCT06458712 reports 13 study locations spanning 4 distinct geographic areas - top geographies include Other, Connecticut, Texas.
Frequently Asked Questions
What is clinical trial NCT06458712 about?
NCT06458712 is a clinical study titled "Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies". Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage inter-participant Dose Escalation Phase followed by a Dose Expansion Phase.
What is the current status of trial NCT06458712?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-11-21. Estimated completion is 2028-08.
What conditions does trial NCT06458712 study?
This clinical trial studies the following conditions: Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases).
What interventions are being tested in trial NCT06458712?
The interventions under investigation include: DSB2455 (DRUG).
Who is sponsoring clinical trial NCT06458712?
This trial is sponsored by Duke Street Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06458712 being conducted?
This trial has 13 study locations across Connecticut, Texas, La Rioja. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.